In the Original Investigation, “Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials,”1 that was published online first on April 12, 2023, and in the May 2023 issue of JAMA Dermatology, the authors have reanalyzed the data after removing 10 patients from 1 center. The corresponding author explains this removal, reanalysis, and corrections in a Letter.2 Corrections affect the Abstract; the Key Points; the Results section of the text; Tables 1, 2, and 3; Figures 1 and 2; and eFigures 2, 3, and 4 and eTables 3, 4, and 5 in Supplement 1. This article has been corrected online.1
Reference
- 1.Paller AS, Ladizinski B, Mendes-Bastos P, et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the Measure Up 1, Measure Up 2, and AD Up randomized clinical trials. JAMA Dermatol. 2023;159(5):526-535. doi: 10.1001/jamadermatol.2023.0391 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Paller AS. Reanalysis of study after removal of participants in 1 trial of upadacitinib for atopic dermatitis. JAMA Dermatol. Published online March 20, 2024. doi: 10.1001/jamadermatol.2024.0194 [DOI] [PubMed] [Google Scholar]
